Mary Mathieu - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Mary Mathieu

Showing results (11-20 of 14) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 14 results.

Cancer Research|September 18, 2014

Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cellsTeemu T Junttila, Ji Li, Jennifer Johnston, et al.

Blood|December 3, 2016

An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemiaSteven R Leong, Siddharth Sukumaran, Maria Hristopoulos, et al.

Science Translational Medicine|May 15, 2015

Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignanciesLiping L Sun, Diego Ellerman, Mary Mathieu, et al.

JCI Insight|April 10, 2020

Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibodyKarin Staflin, Christina L Zuch de Zafra, Leah K Schutt, et al.

Pageof 2

Search research articles

Showing results (11-20 of 14) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 14 results.

Cancer Research|September 18, 2014

Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cellsTeemu T Junttila, Ji Li, Jennifer Johnston, et al.

Blood|December 3, 2016

An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemiaSteven R Leong, Siddharth Sukumaran, Maria Hristopoulos, et al.

Science Translational Medicine|May 15, 2015

Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignanciesLiping L Sun, Diego Ellerman, Mary Mathieu, et al.

JCI Insight|April 10, 2020

Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibodyKarin Staflin, Christina L Zuch de Zafra, Leah K Schutt, et al.

Pageof 2